SEC Form 4 · accession 0000904454-17-000692
ACHILLION PHARMACEUTICALS INC · ACHN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Nov 20, 2017
Accepted (ET)
Nov 22, 2017 · 11:44 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001070336
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 20, 2017 | S | 18,367,346 | $2.75 | D | 0 | I | By Johnson & Johnson Innovation - JJDC, Inc. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.